Skip to main content
OpenTrials
Completed

NCT Number: NCT04799366

Contractile Properties of Hypertrofic Muscles in Patients With Non-Dystrophic Myotonia

In myotonia congenita (MC), mutations in the CLCN1 gene coding a key chloride channel expressed in muscle cells cause myotonia. On examination, the myotonia can be demonstrated as delayed muscle relaxation of muscle contractions after mechanical stimulations. Existing literature describe no muscle weakness in MC patients, however a recent muscle MRI study in non-dystrophic myotonia patients found structural abnormalities in affected muscles when examined using T1 and STIR imaging. The question remains whether the signs of structural changes in the muscle are merely due to the myotonia, or long-term effects of elevated stress of the tissue, and if so, whether those changes lead to clinically significant loss of contractile properties of the muscle.

This study examines if the contractile properties of myotonic muscles are impaired in MC patients. 40 patients with Thomsens disease (n=20) and Beckers disease (n=20), respectively, will be included along with 20 healthy controls. Peak muscle torque is measured in the hand by hand dynamometer and in the thigh and calf muscles with a Biodex System 4 Pro Dynamometer and the cross-sectional area of the muscles are examined on T1-weighed and Dixon-MRI-scan. With the obtained data peak torque in strength tests, muscle hypertrophy, fat fraction in muscle tissue and contractility of the muscles, compared with healthy controls, will be assessed.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age <18 years
  • Molecularly verified MC (Thomsens or Beckers disease)

Exclusion criteria

  • Conditions that may impair results of the study, evaluated by the investigator
  • Clausphobia
  • Pregnancy or breastfeeding
  • Metallic objects in and around the body that are not MR-compatible

Treatment and study plan

Primary outcomes

  1. Contractile properties

    Time frame: 1 year

    To investigate if contractile properties of the muscles are impaired in MC patients compared with healthy controls.

Secondary outcomes

  1. Measuring muscle hypertrophy in upper and lower limbs

    Time frame: 1 year

    Visualizing and measuring hypertrophy on MRI of affected muscles in the forearm, thigh and calf of MC patients compared with muscles in healthy controls.

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Mar 16, 2021
Registry last updated
Mar 30, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.